Osteoprotegerin free (human), detection set



APO-54N-028-KI01	96 wells	530.00 USD

Replaces Prod. #: APO-54N-042

Product Specification

Alternative Name:	Osteoclastogenesis inhibitory factor, Tumor Necrosis Factor receptor superfamily member 11B

Sensitivity:	2pg/ml (range 0 to 250 pg/ml).

Kit/Set Contains:	1 vial Standard (lyophilized) (STD).1 vial Coating Antibody (COAT).1 vial Detection Antibody (DET).

Application:	For the quantitative determination of human free osteoprotegerin (not bound to RANKL or TRAIL) in cell culture supernatant, plasma and serum.

Short Term Storage:	+4°C

Handling:	Avoid freeze/thaw cycles. For long term storage keep the standard (STD) at -20°C.

Miscellaneous/General:	OPG (Osteoprotegerin; also called Osteoclastogenesis Inhibitory Factor or TNFRSF11B) is a secreted member of the TNF (Tumor necrosis factor) receptor superfamily of proteins [1]. OPG, composed of 380 amino acids, is expressed as monomer and secreted as disulphide-homodimeric protein [2]. Produced by numerous cell types and tissues, its expression pattern targets the skeletal, immune, and vascular systems. Osteoblasts secrete OPG that protects the skeleton from excessive bone resorption by acting as a decoy receptor for the ligand nuclear factor-κB ligand (RANKL), preventing it from interacting with its receptor RANK [3]. OPG/RANK/RANKL molecular triumvirat plays a pivotal function in the regulation of the immune system through dendritic cells [4]. OPG-deficient mice exhibit severe osteoporosis and vascular calcification of the aorta and renal arteries [5]. Defects in TNFRSF11B are the cause of juvenile Paget disease (JPD), a bone disease [6]. OPG also functions as a soluble receptor for the TNF ligand TRAIL (TNF-related apoptosis-inducing ligand) preventing it to activate apoptotic signaling cascase and therefore providing cancer cells with a survival advantage [7].

Background / Technical Information:	UniProt ID O00300: Osteoprotegerin (human)

General Literature References

Biology of RANK, RANKL, and osteoprotegerin: B.F. Boyce & L. Xing; Arthritis Res. Ther. 9 Suppl 1, S1 (2007), Abstract;

RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases: M. Baud huin, et al.; Cell Mol. Life Sci. 64, 2334 (2007), Abstract;

Paget’s disease of bone and genetic disorders of RANKL/OPG/RANK/NF-kappaB signaling: M.P. Whyte; Ann. N. Y. Acad. Sci. 1068, 143 (2006), Abstract;

Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis: H. Min, et al.; J. Exp. Med. 192, 463 (2000), Abstract;

Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL: J.G. Emery, et al.; J. Biol. Chem. 273, 14363 (1998), Abstract; Full Text

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation: D.L. Lacey, et al.; Cell 93, 165 (1998), Abstract;

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density: W.S. Simonet, et al.; Cell 89, 309 (1997), Abstract;